Latest Leverage News

Austco Healthcare kicks off FY26 with a robust 51% revenue increase and improved profitability, driven by strong organic growth and strategic acquisitions.

Tolu Minerals confirms multiple high-priority porphyry copper-gold targets at its Mt Penck project in Papua New Guinea, supported by an independent geophysical review and surrounded by active exploration including a major Rio Tinto application.

Power Minerals Limited has advanced its critical minerals portfolio with the acquisition of the Gamma Heavy Rare Earths and Uranium Project in California and completed the Santa Anna Niobium-REE-Gallium Project acquisition in Brazil, supported by a combined $6.7 million capital raise.

Archer Materials has successfully demonstrated that its blood potassium Biochip can be fabricated on a silicon platform, matching clinical accuracy standards and accelerating its path to commercialisation.

Pursuit Minerals progresses its Rio Grande Sur lithium project with a refined commercial plan and feasibility study, while expanding into gold through the Sascha Marcelina acquisition. A recent $4 million placement strengthens its financial position for growth.

Dundas Minerals has leveraged advanced AI technology to identify multiple high-priority gold targets beneath shallow cover in its Gerry Well Greenstone Belt tenements, signaling a promising new chapter in its exploration journey.

Rhythm Biosciences reports strong Q1 FY26 progress, securing strategic partnerships and advancing commercial readiness for its ColoSTAT® colorectal cancer test alongside robust growth in its geneType platform.

INOVIQ Limited has raised $9.5 million to advance its pioneering ovarian cancer screening test and CAR-exosome therapeutic programs, backed by strong preclinical data and strategic partnerships.

Orthocell has appointed MontsMed as the exclusive distributor for its nerve repair product Remplir™ in Hong Kong, marking a significant step in its Asian commercialisation strategy. This move opens access to the vast Guangdong-Hong Kong-Macao Greater Bay Area, complementing existing operations in Singapore and planned expansion in Thailand.

LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.

Canterbury Resources has successfully closed an oversubscribed Share Purchase Plan, raising $1.24 million to advance its copper-gold exploration projects across Australia and Papua New Guinea.

Dimerix Limited reports solid progress in its Phase 3 trial for DMX-200 targeting rare kidney disease FSGS, backed by orphan drug status in Japan and a robust cash position. The company prepares to engage the FDA on new data supporting regulatory approval.